Elicio Therapeutics has reported final Phase 1 data showing its off-the-shelf vaccine ELI-002 2P generated potent and durable immune responses in patients with KRAS-mutant pancreatic and colorectal cancers who had minimal residual disease after standard treatment. Results from the AMPLIFY-201 study, published in Nature Medicine, involved 25 participants—20 with pancreatic ductal adenocarcinoma and five with colorectal cancer—who received subcutaneous doses of the lymph-node-targeted amphiphile vaccine. After a median 19.7-month follow-up, 84 percent of patients mounted KRAS-specific T-cell responses, and 71 percent produced both CD4+ and CD8+ subsets. Patients whose T-cell response exceeded a 9.17-fold increase over baseline had not reached median radiographic relapse-free or overall survival, compared with 3.02 and 15.98 months respectively in lower responders (hazard ratios 0.12 and 0.23). Antigen spreading to additional tumour neoantigens was observed in two-thirds of evaluable patients. No new safety signals emerged. The company is running a randomized Phase 2 trial (NCT05726864) with an expanded seven-peptide formulation to confirm whether the immune activity translates into lower recurrence rates and longer survival. If successful, ELI-002 could offer a readily available, non-personalised vaccine option for cancers driven by KRAS mutations, which occur in roughly 90 percent of pancreatic and 40 percent of colorectal tumours.